Iterum Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2016
Revenue	0	0	0	0	0	0.04	Upgrade
Revenue Growth (YoY)	-	-	-	-	-	-95.74%	Upgrade
Gross Profit	0	0	0	0	0	0.04	Upgrade
Selling, General & Admin	7.56	7.48	12.77	13.83	11.05	11.28	Upgrade
Research & Development	37.54	39.99	17.62	10.71	21.07	90.77	Upgrade
Operating Expenses	45.1	47.47	30.38	24.54	32.13	102.06	Upgrade
Operating Income	-45.1	-47.47	-30.38	-24.54	-32.13	-102.02	Upgrade
Interest Expense / Income	1.52	1.43	2.36	5.55	15.1	0.86	Upgrade
Other Expense / Income	-11.57	-11.14	11.39	60.77	4.04	-0.2	Upgrade
Pretax Income	-35.05	-37.76	-44.13	-90.86	-51.26	-102.69	Upgrade
Income Tax	0.54	0.61	0.3	0.71	0.74	0.44	Upgrade
Net Income	-35.58	-38.37	-44.43	-91.56	-52.01	-103.13	Upgrade
Shares Outstanding (Basic)	15	13	12	11	2	1	Upgrade
Shares Outstanding (Diluted)	15	13	12	11	2	1	Upgrade
Shares Change	21.69%	5.93%	12.35%	580.42%	65.38%	66.22%	Upgrade
EPS (Basic)	-2.65	-2.96	-3.63	-8.41	-32.49	-106.50	Upgrade
EPS (Diluted)	-2.65	-2.96	-3.63	-8.41	-32.49	-106.50	Upgrade
Free Cash Flow	-42.84	-39.34	-18.54	-15.9	-54.54	-81.95	Upgrade
Free Cash Flow Per Share	-2.78	-3.04	-1.51	-1.46	-34.07	-84.67	Upgrade
Gross Margin	-	-	-	-	-	100.00%	Upgrade
Operating Margin	-	-	-	-	-	-275732.43%	Upgrade
Profit Margin	-	-	-	-	-	-278729.73%	Upgrade
Free Cash Flow Margin	-	-	-	-	-	-221475.68%	Upgrade
EBITDA	-32.21	-34.58	-39.97	-83.2	-36.01	-101.67	Upgrade
EBITDA Margin	-	-	-	-	-	-274791.89%	Upgrade
Depreciation & Amortization	1.32	1.75	1.8	2.1	0.16	0.15	Upgrade
EBIT	-33.53	-36.33	-41.77	-85.31	-36.17	-101.83	Upgrade
EBIT Margin	-	-	-	-	-	-275202.70%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).